Osaka, Japan

Hisayuki Takamatsu


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Hisayuki Takamatsu: Innovator in Pharmaceutical Chemistry

Introduction

Hisayuki Takamatsu is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific diseases. With a total of 3 patents to his name, Takamatsu's work is recognized for its innovative approach to treating conditions related to autotaxin.

Latest Patents

Takamatsu's latest patents include groundbreaking work on 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives. One of his notable inventions involves a method for treating or preventing diseases associated with autotaxin. This method includes administering a carboxylic acid compound of a specific formula to patients in need. Another patent focuses on providing a compound that exhibits superior ATX inhibitory action, which is useful for the prophylaxis or treatment of diseases involving autotaxin.

Career Highlights

Hisayuki Takamatsu is currently employed at Mitsubishi Tanabe Pharma Corporation, where he continues to advance his research and development efforts. His work has not only contributed to the scientific community but has also paved the way for new therapeutic options in medicine.

Collaborations

Takamatsu collaborates with talented colleagues, including Taichi Takahashi and Daisuke Iijima. Their combined expertise enhances the innovative environment at Mitsubishi Tanabe Pharma Corporation, fostering the development of new pharmaceutical solutions.

Conclusion

Hisayuki Takamatsu's contributions to pharmaceutical chemistry exemplify the impact of innovation in medicine. His patents reflect a commitment to improving health outcomes through targeted therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…